OS Therapies Incorporated Common Stock (OSTX)

The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the...

ASCO 2026: 2.5-Year Overall Survival DataJefferies Healthcare Conference: Partnering & Investor meetingsBIO International Convention: Panel ParticipationMIB Agents Factor Osteosarcoma Conference:...

$5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to...

New York, New York and Rockville, Maryland--(Newsfile Corp. - May 15, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS...

Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S.,...

Dallas, Texas--(Newsfile Corp. - May 12, 2026) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners updates their coverage...

Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response...

Regulatory feedback recent from April 2026 EU EMA and Australian TGA meetingsRemaining Q2-2026 regulatory meetings include two U.S. FDA meetings...

New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular...

Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions Scientific and medical titan focused on...

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of OS Therapies Incorporated (NYSE American: OSTX) resulting from allegations that OS Therapies may have issued materially misleading business information to the investing public.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of OS Therapies Incorporated (NYSE American: OSTX) resulting from allegations that OS Therapies may have issued materially misleading business information to the investing public.

Senior leadership roles at Guardant Health, Genentech and PfizerRegulatory, clinical and commercial expertise in therapeutics and biomarkersWill assist with osteosarcoma...

Company expects approximately $2 million in non-dilutive VAT refunds from wholly owned U.K. subsidiary in 2Q-26Company expects to receive approximately...

December 2025 Type C Meeting confirmed immune biomarkers suitability to establish surrogate clinical efficacy that could support BLA under Accelerated...

Meetings with all four regulatory agencies scheduled to occur in the second quarter of 2026, with expected Phase 3 commencement...

ATMP benefits include access to the Conditional Marketing Authorisation accelerated market access pathway in Europe, significantly reduced user fees for...

FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussionsOS Therapies on track to complete clinical...

Additional forthcoming biomarker data from human trial expected to further characterize immune pathway activation and its relationship to clinical outcomesU.S.,...

New York, New York--(Newsfile Corp. - February 4, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or...

Request for FDA Rolling Review submitted to FDA on January 30, 2026Non-Clinical and CMC BLA modules submitted to FDAAt FDA's...

Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from short-term survivors (<1year)Pre-specified pathway...

OS Animal Health (OSAH), a wholly-owned subsidiary of OS Therapies (OSTX), targeting Initial Public Offering (IPO) on NYSE American or...

$7.53M gross proceeds raised from pre-existing investors, providing capital runway into 2027All nine investors that were offered agreed to participateNet...